Retrospective Analysis of HER2 Testing, Treatment Patterns, and Clinical Outcomes in Patients With Locally Advanced or Metastatic NSCLC With HER2 Mutations in France.

Fiche publication

Date publication

juin 2026

Journal

Cancer medicine

Auteurs

Membres identifiés du Cancéropôle Est :
Dr DEBIEUVRE Didier

Tous les auteurs :
Debieuvre D, Macouillard P, Quantin X, Berktas M, Girard N, Audigier-Valette C, Filleron T, Musilli S, Bosquet L, Pérol M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42252502

Résumé

HER2 (ERBB2) gene mutations are associated with poor prognosis in non-small cell lung cancer (NSCLC). It is important to identify patients with HER2-mutant (HER2m) NSCLC, as new targeted treatment options are emerging. However, HER2 testing in clinical practice varies across regions, and real-world data on HER2m NSCLC are limited.